IS5547A - Forlyf fyrir tálma við aspartílprótínkljúfum - Google Patents
Forlyf fyrir tálma við aspartílprótínkljúfumInfo
- Publication number
- IS5547A IS5547A IS5547A IS5547A IS5547A IS 5547 A IS5547 A IS 5547A IS 5547 A IS5547 A IS 5547A IS 5547 A IS5547 A IS 5547A IS 5547 A IS5547 A IS 5547A
- Authority
- IS
- Iceland
- Prior art keywords
- prostate
- inhibitors
- protein cleavage
- aspartic
- aspartic protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 230000007026 protein scission Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6888997P | 1997-12-24 | 1997-12-24 | |
PCT/US1998/027424 WO1999033793A2 (en) | 1997-12-24 | 1998-12-23 | Prodrugs of aspartyl protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IS5547A true IS5547A (is) | 2000-06-22 |
Family
ID=22085350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS5547A IS5547A (is) | 1997-12-24 | 2000-06-22 | Forlyf fyrir tálma við aspartílprótínkljúfum |
Country Status (21)
Country | Link |
---|---|
US (2) | US20020082249A1 (is) |
EP (1) | EP1042280A2 (is) |
JP (1) | JP2001527062A (is) |
KR (1) | KR20010033595A (is) |
CN (1) | CN1110492C (is) |
AP (1) | AP2000001856A0 (is) |
AU (1) | AU2092599A (is) |
BR (1) | BR9814484A (is) |
CA (1) | CA2316218A1 (is) |
EA (1) | EA200000702A1 (is) |
EE (1) | EE200000386A (is) |
HR (1) | HRP20000499A2 (is) |
HU (1) | HUP0101598A3 (is) |
ID (1) | ID25551A (is) |
IL (1) | IL136940A0 (is) |
IS (1) | IS5547A (is) |
NO (1) | NO20003332L (is) |
PL (1) | PL341762A1 (is) |
SK (1) | SK9672000A3 (is) |
TR (1) | TR200002402T2 (is) |
WO (1) | WO1999033793A2 (is) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
CZ304273B6 (cs) | 2001-02-14 | 2014-02-12 | Tibotec Pharmaceuticals Ltd. | 2-(Substitovaná-amino)benzothiazolsulfonamidová sloučenina, způsob její přípravy a farmaceutická kompozice s jejím obsahem |
NZ528954A (en) | 2001-04-09 | 2005-04-29 | Tibotec Pharm Ltd | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
WO2002088101A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
PL209029B1 (pl) | 2001-05-11 | 2011-07-29 | Tibotec Pharm Ltd | Pochodne 2-aminobenzoksazolo-sulfonamidów jako inhibitory proteazy HIV, oraz kompozycje zawierające te związki |
BR0215260A (pt) | 2001-12-21 | 2004-12-07 | Tibotec Pharm Ltd | Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro |
MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
MXPA04010527A (es) * | 2002-04-26 | 2004-12-13 | Gilead Sciences Inc | Acumulacion celular de analogos de fosfonato de los compuestos inhibidores de la proteasa del virus de inmunodeficiencia humana (vih). |
IL165043A0 (en) | 2002-05-17 | 2005-12-18 | Tibotec Pharm Ltd | broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors |
MXPA05001792A (es) | 2002-08-14 | 2005-04-25 | Tibotec Pharm Ltd | Oxindolsulfonamida sustituida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro. |
DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
US6632816B1 (en) * | 2002-12-23 | 2003-10-14 | Pharmacor Inc. | Aromatic derivatives as HIV aspartyl protease inhibitors |
ES2305887T3 (es) | 2003-12-18 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos. |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
EP1789107B1 (en) | 2004-08-30 | 2009-05-27 | Interstitial Therapeutics | Medical stent provided with inhibitors of atp synthesis |
US20080125432A1 (en) | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
EP2460408A1 (en) | 2004-12-17 | 2012-06-06 | deVGen N.V. | Nematicidal compositions |
WO2007045496A1 (en) | 2005-10-21 | 2007-04-26 | Universiteit Antwerpen | Novel urokinase inhibitors |
AR058238A1 (es) | 2005-11-28 | 2008-01-23 | Tibotec Pharm Ltd | Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih |
TWI385173B (zh) | 2005-11-28 | 2013-02-11 | Tibotec Pharm Ltd | 作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物 |
CA2632095A1 (en) | 2005-11-30 | 2007-06-07 | Ambrilia Biopharma Inc. | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
AU2007274284B2 (en) | 2006-07-13 | 2012-04-26 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
CA2662449A1 (en) | 2006-09-08 | 2008-03-13 | Bayer Schering Pharma Aktiengesellschaft | Compounds and methods for 18f labeled agents |
AU2007337830A1 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Benzenesulfonamide derivatives as HIV protease inhibitors |
JP5536647B2 (ja) | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロロピリミジン |
EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
ES2424982T3 (es) | 2008-03-10 | 2013-10-10 | Janssen Pharmaceutica, N.V. | 4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK |
EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
EP2501431B1 (en) | 2009-11-19 | 2020-01-08 | Wellinq Medical B.V. | Narrow profile composition-releasing expandable medical balloon catheter |
WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
EP4092120A1 (en) | 2011-06-21 | 2022-11-23 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (anglptl3) irna compositions and methods of use thereof |
EP3597750B1 (en) | 2011-06-23 | 2022-05-04 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
EP2700396A3 (en) | 2012-06-20 | 2015-04-29 | Sylphar Nv | Strip for the delivery of oral care compositions |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
SI2929031T1 (en) | 2012-12-05 | 2018-02-28 | Alnylam Pharmaceuticals, Inc. | PCSK9 IRNA assemblies and procedures for their use |
MX366660B (es) | 2013-03-14 | 2019-07-18 | Alnylam Pharmaceuticals Inc | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. |
EP2999785B1 (en) | 2013-05-22 | 2018-04-04 | Alnylam Pharmaceuticals, Inc. | Serpina1 irna compositions and methods of use thereof |
IL293657A (en) | 2013-05-22 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Preparations of tmprss6 irna and methods of using them |
KR102344559B1 (ko) | 2013-12-12 | 2021-12-31 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 iRNA 조성물 및 이의 이용 방법 |
EP3960860A3 (en) | 2014-02-11 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療serpinc1相關疾患之方法和組成物 |
JP6811094B2 (ja) | 2014-05-22 | 2021-01-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | アンジオテンシノーゲン(AGT)iRNA組成物およびその使用 |
EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
IL295159A (en) | 2015-04-13 | 2022-09-01 | Alnylam Pharmaceuticals Inc | Preparations of angiopoietin-like 3 irna and methods of using them |
WO2016176437A1 (en) | 2015-04-28 | 2016-11-03 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
TWI806034B (zh) | 2015-05-06 | 2023-06-21 | 美商阿尼拉製藥公司 | 第十二因子(哈格曼因子)(F12)、激肽釋放素B、血漿(夫列契因子)1(KLKB1)及激肽原1(KNG1)iRNA組成物及其使用方法 |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
KR20230119027A (ko) | 2015-12-07 | 2023-08-14 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
TWI790217B (zh) | 2016-12-16 | 2023-01-21 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法 |
EP3621963B1 (en) | 2017-05-11 | 2024-01-24 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
SG11202100715WA (en) | 2018-08-13 | 2021-02-25 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
SG11202107669WA (en) | 2019-01-16 | 2021-08-30 | Genzyme Corp | Serpinc1 irna compositions and methods of use thereof |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
JP2023514443A (ja) | 2020-02-24 | 2023-04-05 | カトリーケ、ユニベルシテート、ルーベン | ピロロピリジンおよびイミダゾピリジン抗ウイルス化合物 |
EP4267579A1 (en) | 2020-12-22 | 2023-11-01 | Luxembourg Institute of Health (LIH) | Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases |
EP4301369A1 (en) | 2021-03-04 | 2024-01-10 | Universiteit Antwerpen | Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer |
AU2022286613A1 (en) | 2021-05-31 | 2023-11-23 | Telix Pharmaceuticals (Innovations) Pty Ltd | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
WO2024062043A1 (en) | 2022-09-21 | 2024-03-28 | Universiteit Antwerpen | Substituted phenothiazines as ferroptosis inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
ATE174587T1 (de) * | 1993-08-24 | 1999-01-15 | Searle & Co | Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
-
1998
- 1998-12-23 AP APAP/P/2000/001856A patent/AP2000001856A0/en unknown
- 1998-12-23 KR KR1020007007108A patent/KR20010033595A/ko not_active Application Discontinuation
- 1998-12-23 TR TR2000/02402T patent/TR200002402T2/xx unknown
- 1998-12-23 AU AU20925/99A patent/AU2092599A/en not_active Withdrawn
- 1998-12-23 EA EA200000702A patent/EA200000702A1/ru unknown
- 1998-12-23 CA CA002316218A patent/CA2316218A1/en not_active Abandoned
- 1998-12-23 PL PL98341762A patent/PL341762A1/xx not_active Application Discontinuation
- 1998-12-23 EP EP98965466A patent/EP1042280A2/en not_active Withdrawn
- 1998-12-23 ID IDW20001410A patent/ID25551A/id unknown
- 1998-12-23 IL IL13694098A patent/IL136940A0/xx unknown
- 1998-12-23 JP JP2000526477A patent/JP2001527062A/ja active Pending
- 1998-12-23 HU HU0101598A patent/HUP0101598A3/hu unknown
- 1998-12-23 EE EEP200000386A patent/EE200000386A/xx unknown
- 1998-12-23 WO PCT/US1998/027424 patent/WO1999033793A2/en not_active Application Discontinuation
- 1998-12-23 BR BR9814484-7A patent/BR9814484A/pt not_active Application Discontinuation
- 1998-12-23 CN CN98813313A patent/CN1110492C/zh not_active Expired - Fee Related
- 1998-12-23 SK SK967-2000A patent/SK9672000A3/sk unknown
-
2000
- 2000-06-22 IS IS5547A patent/IS5547A/is unknown
- 2000-06-26 NO NO20003332A patent/NO20003332L/no not_active Application Discontinuation
- 2000-07-24 HR HR20000499A patent/HRP20000499A2/hr not_active Application Discontinuation
-
2001
- 2001-11-30 US US09/998,617 patent/US20020082249A1/en not_active Abandoned
-
2002
- 2002-08-21 US US10/226,430 patent/US20030144217A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP2000001856A0 (en) | 2000-09-30 |
WO1999033793A3 (en) | 1999-09-10 |
US20030144217A1 (en) | 2003-07-31 |
KR20010033595A (ko) | 2001-04-25 |
PL341762A1 (en) | 2001-05-07 |
CA2316218A1 (en) | 1999-07-08 |
HUP0101598A3 (en) | 2002-08-28 |
IL136940A0 (en) | 2001-06-14 |
ID25551A (id) | 2000-10-12 |
BR9814484A (pt) | 2000-10-10 |
NO20003332D0 (no) | 2000-06-26 |
NO20003332L (no) | 2000-08-18 |
SK9672000A3 (en) | 2001-04-09 |
JP2001527062A (ja) | 2001-12-25 |
EA200000702A1 (ru) | 2000-12-25 |
AU2092599A (en) | 1999-07-19 |
HUP0101598A2 (hu) | 2002-04-29 |
WO1999033793A2 (en) | 1999-07-08 |
CN1284072A (zh) | 2001-02-14 |
EE200000386A (et) | 2001-12-17 |
TR200002402T2 (tr) | 2001-01-22 |
US20020082249A1 (en) | 2002-06-27 |
EP1042280A2 (en) | 2000-10-11 |
CN1110492C (zh) | 2003-06-04 |
HRP20000499A2 (en) | 2001-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS5547A (is) | Forlyf fyrir tálma við aspartílprótínkljúfum | |
IS5546A (is) | Súlfonamíð afleiður sem forlyf fyrir tálma við aspartílprótínkljúfum | |
NO995433D0 (no) | Protease-inhibitorer | |
NO990548L (no) | Inhibitorer for cystein-protease | |
DK1114051T3 (da) | Inhibitorer for p38 | |
NO20004550D0 (no) | Enzyminhibitorer | |
ATE264339T1 (de) | Serine protease inhibitoren | |
NO20004219L (no) | Inhibitorer av fosfolipaseenzymer | |
NO20004220L (no) | Inhibitorer av fosfolipaseenzymer | |
NO20004526D0 (no) | Modulatorer for proteintyrosinfosfataser | |
NO20012980D0 (no) | Proteaseinhibitorer | |
ID24076A (id) | Inhibitor-inhibitor protein transferase farnesil | |
NO996578D0 (no) | Urokinase-inhibitorer | |
ATE446389T1 (de) | Enzymgemisch | |
ID20637A (id) | Metode untuk menghambat pembentukan sulfida biogenik | |
DK1027332T3 (da) | Hidtil ukendte lactametalloproteaseinhibitorer | |
NO992734D0 (no) | Serin-protease inhibitorer | |
DK0958287T3 (da) | Sulfamidmetalloprotease-inhibitorer | |
NO983688D0 (no) | Serin-protease-inhibitorer | |
NO995434L (no) | Proteaseinhibitorer | |
PT927183E (pt) | Inibidores espirociclicos de metaloproteases | |
ID22650A (id) | Penggunaan penghambat-penghambat lipase usus lambung | |
NO995435D0 (no) | Protease-inhibitorer | |
NO995268D0 (no) | Proteaseinhibitorer | |
DE69730871D1 (de) | Serine-protease-inhibitoren |